C07D 241/40
Benzopyrazines
C07D241/40 (Benzopyrazines) appears on 1,161 US grants and 1,010 published applications in this corpus.
Search patents in C07D- Granted patents
- 1,161
- Published applications
- 1,010
- Assignees
- 595
- Inventors
- 3,771
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 14 | 0 |
| 1977 | 6 | 0 |
| 1978 | 13 | 0 |
| 1979 | 11 | 0 |
| 1980 | 10 | 0 |
| 1981 | 14 | 0 |
| 1982 | 16 | 0 |
| 1983 | 7 | 0 |
| 1984 | 17 | 0 |
| 1985 | 15 | 0 |
| 1986 | 10 | 0 |
| 1987 | 13 | 0 |
| 1988 | 10 | 0 |
| 1989 | 19 | 0 |
| 1990 | 24 | 0 |
| 1991 | 10 | 0 |
| 1992 | 18 | 0 |
| 1993 | 29 | 0 |
| 1994 | 12 | 0 |
| 1995 | 15 | 0 |
| 1996 | 22 | 0 |
| 1997 | 35 | 0 |
| 1998 | 37 | 0 |
| 1999 | 28 | 0 |
| 2000 | 23 | 0 |
| 2001 | 28 | 7 |
| 2002 | 32 | 36 |
| 2003 | 35 | 46 |
| 2004 | 26 | 62 |
| 2005 | 19 | 52 |
| 2006 | 30 | 37 |
| 2007 | 24 | 34 |
| 2008 | 25 | 41 |
| 2009 | 33 | 39 |
| 2010 | 24 | 62 |
| 2011 | 28 | 45 |
| 2012 | 39 | 38 |
| 2013 | 35 | 33 |
| 2014 | 41 | 44 |
| 2015 | 36 | 53 |
| 2016 | 40 | 42 |
| 2017 | 34 | 32 |
| 2018 | 32 | 43 |
| 2019 | 30 | 32 |
| 2020 | 32 | 34 |
| 2021 | 26 | 33 |
| 2022 | 16 | 35 |
| 2023 | 14 | 36 |
| 2024 | 13 | 37 |
| 2025 | 20 | 30 |
| 2026 | 21 | 27 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Tautomeric ligand enables biomimetic C—H hydroxylation with molecular oxygen22 Sep 2026US 12,741,937 B2The Scripps Research Institute
- RNA-targeting ligands, compositions thereof, and methods of making and using the same22 Sep 2026US 12,741,945 B2The University of North Carolina at Chapel Hill
- Benzothiazole and quinoline derivatives and their use22 Sep 2026US 12,741,948 B2Shanghai Yao Yuan Biotechnology Co., Ltd.
- Methods and compositions for targeting Tregs using CCR8 inhibitors28 Jul 2026US 12,692,239 B2Nanjing Immunophage Biomedical Co., Ltd.
- Anti-inflammatory carboxamide derivatives21 Jul 2026US 12,686,657 B2Biomedcode Hellas SA
- Method for Treating Phosphorus-Containing Wastewater Produced During Preparation of Sulfonamide Compound8 Oct 2026US 2026/0308035 A1Nanhai Beisha Pharmaceutical Co., Ltd.
- Modulators of sortilin activity24 Sep 2026US 2026/0285802 A1
- Nitrogen-containing hetreocycles for organic electroluminescent devices27 Aug 2026US 2026/0255779 A1Merck Patent GmbH
- Heterocyclic compound, organic light-emitting element comprising same, and composition for organic layer27 Aug 2026US 2026/0255871 A1Lt Materials Co., Ltd.
- Organic compound, solar cell, and application thereof27 Aug 2026US 2026/0255872 A1Contemporary Amperex Future Energy Research Institute (Shanghai) Limited
Most cited
By later US patents
- Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases232US 6,180,632 B2Aventis Pharmaceuticals Products Inc. · 2001
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase226US 5,480,883 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1996
- Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases219US 6,482,834 B2Aventis Pharmaceuticals Inc. · 2002
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase209US 5,409,930 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1995
- Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases207US 6,245,760 B1Aventis Pharmaceuticals Products Inc. · 2001